Evidence map›Paper›PMID 31257351›Full record

Trial reportJournal of clinical and experimental hematopathology : JCEH

Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.

Dai Maruyama, Hirokazu Nagai, Noriko Fukuhara, Toshiyuki Kitano, Takayuki Ishikawa, Tomoaki Nishikawa

Abstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical and experimental hematopathology : JCEH. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dai MaruyamaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Hirokazu NagaiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Noriko FukuharaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Toshiyuki KitanoDepartment of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Tomoaki NishikawaJanssen Pharmaceutical K.K., Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdenineAntineoplastic AgentsDrug Resistance, NeoplasmHumansJapanLymphoma, Mantle-CellMolecular Targeted TherapyPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesRecurrenceRetreatmentTreatment OutcomeAdenineAntineoplastic AgentsibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinescovalent BTK inhibitoribrutinibJapanese patientsmantle cell lymphomaphase II clinical trial

Identifiers

PMID31257351
PMCPMC6661957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.